NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ:WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ:KLTO), and has launched a new website, www.klothoneuro.com. The name and ticker change will have no impact on current shareholders, and there is no action required on their part. The new name embodies the Company's commitment to strategically direct its core investments of time and financial resources toward the multibillion-dollar market opportunities for the company's patented Klotho gene technology assets in the neurosciences sector. Through its exclusive worldwide license, the company's patent protected secr

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. ANEW has secured exclusive worldwide rights and issued patents in the USA, Canada, Europe, Hong Kong and China, covering the secreted form of Klotho, known scientifically as s-KL. Klotho is often referred to as "the anti-aging gene." It is named after the

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW's balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in long-term debt not only clears ANEW's balance sheet but also significantly increases stockholder equity, positioning the company for future growth and investment opportunities. It also eliminates $600,000 in annual interest payments owed by the company. The avera

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company") (NASDAQ:WENA) announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke ("TTS") regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have been introduced including creams, patches, inhalers, liquid autoinjectors, but they have significant cost and formulation limitations for topical applications. Th

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company's Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. "Jeff LeBlanc is a highly experienced senior executive, and we are absolutely delighted to welcome him to our team," commented, Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW. "Jeff has over 20 years of experience in managing financial ope

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the grant and issuance of U.S. Patent No. 12,036,268 ("the 268 patent") covering the secreted RNA splice variant of the human Klotho gene, referred to as "s-KL", for the treatment of cognitive and neurodegenerative diseases. The human Klotho gene, sometimes referred to as the "anti-aging" gene, also controls many normal brain and neurologic functions. The Klotho gene-therapy patent in the U.S. is instrumental new intellectual property ("IP") protec

Melanocortin receptors on neurons in the brain control feeding and weight lossPatented peptide molecules delivered orally as a pill can control feeding disorders and weight loss NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA) has announced that, as a result of its worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona, it plans to pursue the development of therapeutics using novel proprietary peptides that selectively bind and activate melanocortin receptors on neuronal cells in the brain. The neurobiology of overeating and obesity is well known, and the melanocortin-3 and melanocortin-4 receptors are definitively invol

Patents issued in mainland China protect the Company's novel secreted Klotho protein and Its gene delivery systemRecent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer's Disease and other neurodegenerative diseases NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for the treatment of neurodegenerative diseases to include Alzheimer's disease, Parkins

Genomics data suggests having an active Klotho gene sequence may help people live longer, healthier lives The Company was granted patents in Europe, China, and Hong Kong and awaits issuance of patents in the U.S. and Canada NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA) ("ANEW"), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders, announces plans to advance its recently patented Klotho gene therapy program for neurodegenerative disorders. ANEW has compelling initial data suggesting that maintaining elevated levels of Klotho in the body significantly contributes to long

Collaboration focuses on research and development of ANEW's patented Klotho gene therapy in enhancing longevity and reducing age-related diseases ANEW's mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders and specialty diagnostics, announces a strategic partnership with Drs. Makoto Suzuki, Craig and Bradley Willcox, Richard Al

4 - ANEW Medical, Inc. (0001907223) (Issuer)

3 - ANEW Medical, Inc. (0001907223) (Issuer)

EFFECT - ANEW Medical, Inc. (0001907223) (Filer)

S-1 - ANEW Medical, Inc. (0001907223) (Filer)

8-K - ANEW Medical, Inc. (0001907223) (Filer)

8-K - ANEW Medical, Inc. (0001907223) (Filer)

8-K - ANEW Medical, Inc. (0001907223) (Filer)

10-Q - ANEW Medical, Inc. (0001907223) (Filer)

NT 10-Q - ANEW Medical, Inc. (0001907223) (Filer)

8-K - ANEW Medical, Inc. (0001907223) (Filer)

8-K - ANEW Medical, Inc. (0001907223) (Filer)

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company's Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. "Jeff LeBlanc is a highly experienced senior executive, and we are absolutely delighted to welcome him to our team," commented, Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW. "Jeff has over 20 years of experience in managing financial ope

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company") (NASDAQ:WENA) announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke ("TTS") regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have been introduced including creams, patches, inhalers, liquid autoinjectors, but they have significant cost and formulation limitations for topical applications. Th

SC 13G - ANEW Medical, Inc. (0001907223) (Subject)